The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study.

Young, Jade N; Verma, Hannah; El Kashlan, Nour; Poplausky, Dina; Lamb, Angela J; Guttman-Yassky, Emma; Gulati, Nicholas

Young, Jade N; Verma, Hannah; El Kashlan, Nour; Poplausky, Dina; Lamb, Angela J; Guttman-Yassky, Emma; Gulati, Nicholas.

Afiliación

Young JN; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Verma H; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
El Kashlan N; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Poplausky D; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Lamb AJ; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Guttman-Yassky E; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Gulati N; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.

JAAD Case Rep ; 43: 1-3, 2024 Jan.

Article en En | MEDLINE | ID: mdl-38090670

Palabras clave

biologics; cirAE; cutaneous immune-related adverse event; immune checkpoint inhibitor; immunotherapy; oncodermatology

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: JAAD Case Rep Año: 2024 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: JAAD Case Rep Año: 2024 Tipo del documento: Article